Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy

[(223)Ra]RaCl(2) dichloride treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with improved overall survival (OS) and a delay in the time to the first symptomatic skeletal-related event. The aim of this study was to evaluate the quality of life (QoL) of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Medicine (Baltimore)
Autors principals: Sraieb, Miriam, Hirmas, Nader, Conrad, Rupert, Marinova, Milka, Essler, Markus, Herrmann, Ken, Ahmadzadehfar, Hojjat
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2020
Matèries:
5700
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7505355/
https://ncbi.nlm.nih.gov/pubmed/32957385
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000022287
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars